Leaf Ventures Ii, L.P.Delag... Net Worth

The estimated Net Worth of Leaf Ventures Ii, L.P.Delag... is at least $130 Milion dollars as of 25 October 2016. Leaf Delag owns over 25,000 units of iRhythm Technologies Inc stock worth over $130,323,105 and over the last 8 years Leaf sold IRTC stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Leaf Delag IRTC stock SEC Form 4 insiders trading

Leaf has made over 1 trades of the iRhythm Technologies Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Leaf bought 25,000 units of IRTC stock worth $425,000 on 25 October 2016.

The largest trade Leaf's ever made was buying 25,000 units of iRhythm Technologies Inc stock on 25 October 2016 worth over $425,000. On average, Leaf trades about 25,000 units every 0 days since 2016. As of 25 October 2016 Leaf still owns at least 1,741,589 units of iRhythm Technologies Inc stock.

You can see the complete history of Leaf Delag stock trades at the bottom of the page.

Insiders trading at iRhythm Technologies Inc

Over the last 8 years, insiders at iRhythm Technologies Inc have traded over $124,847,276 worth of iRhythm Technologies Inc stock and bought 150,000 units worth $2,550,000 . The most active insiders traders include Holdings A/S Novo, Vijay K Lathi a Kevin M King. On average, iRhythm Technologies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,872,546. The most recent stock trade was executed by Brice Bobzien on 9 August 2024, trading 1,372 units of IRTC stock currently worth $96,506.

What does iRhythm Technologies Inc do?

irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.

Complete history of Leaf Delag stock trades at iRhythm Technologies Inc

iRhythm Technologies Inc executives and stock owners

iRhythm Technologies Inc executives and other stock owners filed with the SEC include:

• Kevin King,
  President, Chief Executive Officer, Director
• David Vort,
  Executive Vice President - Sales
• Mark Day,
  Executive Vice President of Research and Development
• Kevin M. King,
  Consultant & Director
• Matthew C. Garrett,
  Advisor
• Daniel G. Wilson,
  Exec. VP of Strategy, Corp. Devel. & Investor Relations
• Douglas J. Devine,
  COO, CFO & Sec.
• David A. Vort,
  Exec. VP of Sales & Chief Commercial Officer
• Mark J. Day Ph.D.,
  Exec. VP of R&D
• Abhijit Talwalkar,
  Independent Chairman of the Board
• Mark Rubash,
  Independent Director
• Raymond Scott,
  Independent Director
• Bruce Bodaken,
  Independent Director
• Ralph Snyderman,
  Independent Director
• Cathleen Noel Merz,
  Independent Director
• Douglas Devine,
  Chief Financial Officer
• Renee Budig,
  Independent Director
• Mazi Kiani,
  Sr. VP of Quality & Regulatory
• Dietra N. Jones,
  Exec. VP of Clinical Operations
• Reyna M. Fernandez,
  Exec. VP & Chief HR Officer
• Dr. Mintu P. Turakhia M.D.,
  Chief Medical Officer & Chief Scientific Officer
• Allan B. Wilsker,
  Exec. VP of Information Technology & Customer Service
• Patrick Michael Murphy J.D.,
  Gen. Counsel
• Quentin S. Blackford,
  Pres & CEO
• Judith C. Lenane,
  Chief Clinical Officer & Exec. VP of Operations
• Kaja J. Odegard,
  VP of HR
• Marga Ortigas-Wedekind,
  Exec. VP of Marketing
• Michael J. Coyle,
  Pres, CEO & Director
• Tiba Aynechi,
  Director
• Life Science Partners L P S...,
  
• Venture Partners Xi, Lp Cro...,
  
• Matthew C. Garrett,
  Chief Financial Officer
• Life Science Partners L P S...,
  
• Holdings A/S Novo,
  10% owner
• Clercq Casper L. De,
  Director
• Michael J Coyle,
  President and CEO
• Vijay K Lathi,
  Director
• Karim Karti,
  Former Chief Operating Officer
• Derrick Sung,
  EVP, Strat Corp Development
• Mojdeh Poul,
  Director
• Brian B Yoor,
  Director
• Karen Ling,
  Director
• Mervin Smith,
  EVP Strategic Business Ops
• Marc W. Rosenbaum,
  Chief Accounting Officer
• Daniel G. Wilson,
  EVP, Corp Dev Inv Rel
• Brice Bobzien,
  Chief Financial Officer
• Quentin S. Blackford,
  President and CEO
• Minang Turakhia,
  EVP, CMO & CSO
• Reyna M Fernandez,
  EVP, Chief HR Officer
• Chad Patterson,
  Chief Commercial Officer
• Sumi Shrishrimal,
  EVP, Chief Risk Officer
• Patrick Michael Murphy,
  CBO and CLO